Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion type Assertion NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_head.
- NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion description "[For molecular imaging strategies, a putative panel consisting of markers for EGFR, IGF1-R, FGFR2, GLUT1, CAXII, CD44v6 was positive in 77% of cases and might be considered for development of molecular tracers for male breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_provenance.
- NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion evidence source_evidence_literature NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_provenance.
- NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion SIO_000772 23308200 NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_provenance.
- NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion wasDerivedFrom befree-20150227 NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_provenance.
- NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_assertion wasGeneratedBy ECO_0000203 NP276897.RAIKM9r51vmO6PE-Q6oif0mZGVqyzJ9onmlLydrjX2qHU130_provenance.